Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
i can’t wait to see ex’s reply to this
UCLA explicitly calling out DCVax. final nail in the coffin for “ATL-DC =\= DCVax”
do we know for sure they’re the same person?
uh isn’t this massive?
LL’s presentation is over (session was 8am - noon EST)—anyone have access/updates?
nobody wants to read this stuff man, pointless bickering is annoying for everyone else. stop posting so much
anyone have deets on the LL talk this weekend?
hey thermo, thanks for your insights. after reading the 10Q, do you know why Q2 might’ve had such low revenue reported, given the supposed backlog of compassionate use inquiries?
yes, I mean the contents. as in, whether the data package / evidence that’s part of the MAA is the same data package / evidence that NICE is looking for, albeit submitted two places.
is the NICE “evidence submission” different from the MAA submission?
not really rational to think people are stupid for not knowing what your profession is. you don’t know mine, and i hardly know anyone’s here. I thought you said you were in IT a couple years back. idk why that’d make you angry.
anywho, you dodged my actual question.
works in IT, and perceives “IT person” as an insult? huh.
ex, please let me know your reasoning out of the question i posed here: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172532155
you must have thought of this, and justified to yourself why it could be brushed off.
curious if you think you’ve caught something here that the JAMA authors and reviewers did not. it’s possible none of them saw what you see—that, even though you’re not trained in this, you’re just inherently gifted—or that they saw it and ignored it, putting their reputations on the line?
how did this get past all the experts, but you picked up on it? actually curious what your thinking is on this.
this is reverse p-hacking, and why endpoints are determined before data is unblinded. if this component were integrated into an endpoint, that would be an issue—but the ECA and endpoints were vetted thoroughly before unblinding. with any trial, you can scrounge after the fact and find some subcategory or factor that looks to be causal/SS, but it’s moot. I know it didn’t turn out the way you wanted and the whole thing seems unfair to you, but it is what it is.
Another math question:
If you’ve spent on average 45 minutes on this board every single day for the past 12 years, how much of your life have you wasted on a penny stock board you’re not even invested in?
Answer: 274 12-hr days. Almost an entire waking year of your life.
updates on $3M prepayment?
it is, in one word, bizarre.
thanks Lykiri, do we know if this charity has held any sway with NHS before?
(too bad I get a 404 Error when clicking on the DCVax link in the article)
especially with Dr Mulholland involved, why was DCVax not mentioned?
has anyone heard from DI recently?
hey thermo—sounds of anything blooming?
thanks
right, I think the “was not” was meant to be “has not been”
overall I actually think it sounds positive—they say it’s had a major impact on their treatment and they want an in-house study to advance findings on their own population
sorry i’m lost—why wouldn’t he give a shout out to Shashi Murthy?
in the remote chance this has anything to do with dcvax, i don’t see how it wouldn’t have leaked
put another way, this is just a pile of boxes about the volume of a table.
.07mm avg page thickness * 700,000 -> 160ft -> 104 cubic feet, or 5x5x4 small boxes assuming 1 cubic foot per box. this amount of paper was commonplace at the engineering office i used to work at
I think this should be stickied
can data outside of the PhIII trial—from combo trials, compassionate use, etc.—be considered by regulators in their approval decision?
it’s great they’ve found a way to improve DCVax, but how does that help us with regard to regulatory decisions based on PhIII data?
why are BPs starting trials with DC vaccines if they don’t work?
question is, can/will these increases be considered in regulatory decisions?
based on MAA PR or something else?
anyone seen anything like this before? any examples of prepayments at other companies?
or people just dumping warrants when the price is right?
any thoughts on the DCVax-only results here? DC + poly iclc looks amazing
There is now an update to the preliminary results for the $NWBO UCLA DCVax-L + Poly-ICLC Combo trial.
— Tommy Bax 🇬🇧 🇹🇼 (@TommyBaxendale) April 26, 2023
In Oct 2022 the slide deck was updated for Dr Liau's presentation. The KM Curve now shows a ~50% Overall Survival now approaching 10 YEARS. Pretty phenomenal stuff! pic.twitter.com/bNIx81pZGm
then what is flipper alluding to here:
is it 80 or 150 days for MAA review? I see both on this board, both with references to MHRA site and am confused. thanks.
does anyone know when we expect an update on these trials?
thanks, I only see up to docket 94 there (https://www.pacermonitor.com/public/case/47001949/Northwest_Biotherapeutics,_Inc_v_Canaccord_Genuity_LLC_et_al)
perhaps recent uploads are paywalled. do you see any significant updates?
aren’t we supposed to hear an update from Cohen Milstein today?